{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2024,6,22]],"date-time":"2024-06-22T13:23:09Z","timestamp":1719062589806},"reference-count":29,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T00:00:00Z","timestamp":1691625600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int Ophthalmol"],"DOI":"10.1007\/s10792-023-02655-9","type":"journal-article","created":{"date-parts":[[2023,8,10]],"date-time":"2023-08-10T12:09:54Z","timestamp":1691669394000},"page":"3445-3452","update-policy":"http:\/\/dx.doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Clinical outcomes of different regimens of intravitreal Conbercept for the treatment of choroidal neovascularization secondary to pathological myopia"],"prefix":"10.1007","volume":"43","author":[{"given":"Li","family":"Song","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Chunyun","family":"Luo","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yu","family":"Zheng","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Xiangyin","family":"Sha","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2023,8,10]]},"reference":[{"issue":"1","key":"2655_CR1","doi-asserted-by":"publisher","first-page":"99","DOI":"10.1038\/s41572-020-00231-4","volume":"6","author":"PN Baird","year":"2020","unstructured":"Baird PN, Saw SM, Lanca C et al (2020) Myopia. Nat Rev Dis Primers 6(1):99","journal-title":"Nat Rev Dis Primers"},{"key":"2655_CR2","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2020.615902","volume":"7","author":"J Xie","year":"2020","unstructured":"Xie J, Chen Q, Yu J et al (2020) Morphologic features of myopic choroidal neovascularization in pathologic myopia on swept-source optical coherence tomography. Front Med (Lausanne) 7:615902","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"2655_CR3","doi-asserted-by":"publisher","first-page":"1489","DOI":"10.1016\/j.ophtha.2015.03.018","volume":"122","author":"KM Williams","year":"2015","unstructured":"Williams KM, Bertelsen G, Cumberland P et al (2015) Increasing prevalence of myopia in Europe and the impact of education. Ophthalmology 122(7):1489\u20131497","journal-title":"Ophthalmology"},{"issue":"1","key":"2655_CR4","doi-asserted-by":"publisher","first-page":"81","DOI":"10.1007\/s00417-020-04795-5","volume":"259","author":"RM Coco-Martin","year":"2021","unstructured":"Coco-Martin RM, Belani-Raju M, de la Fuente-Gomez D, SanabriaI MR, Fern\u00e1ndez (2021) Progression of myopic maculopathy in a Caucasian cohort of highly myopic patients with long follow-up: a multistate analysis. Graefes Arch Clin Exp Ophthalmol 259(1):81\u201392","journal-title":"Graefes Arch Clin Exp Ophthalmol"},{"issue":"6","key":"2655_CR5","doi-asserted-by":"publisher","first-page":"863","DOI":"10.1016\/j.ophtha.2017.12.005","volume":"125","author":"Y Fang","year":"2018","unstructured":"Fang Y, Yokoi T, Nagaoka N et al (2018) Progression of myopic maculopathy during 18-year follow-up. Ophthalmology 125(6):863\u2013877","journal-title":"Ophthalmology"},{"issue":"1","key":"2655_CR6","doi-asserted-by":"publisher","first-page":"48","DOI":"10.1097\/ICL.0000000000000201","volume":"42","author":"NS Chan","year":"2016","unstructured":"Chan NS, Teo K, Cheung CM (2016) Epidemiology and diagnosis of myopic choroidal neovascularization in Asia. Eye Contact Lens 42(1):48\u201355","journal-title":"Eye Contact Lens"},{"issue":"41","key":"2655_CR7","doi-asserted-by":"publisher","first-page":"4853","DOI":"10.2174\/1381612825666190124102641","volume":"24","author":"H Isildak","year":"2018","unstructured":"Isildak H, Schwartz SG, Flynn HW (2018) Pharmacotherapy of myopic choroidal neovascularization. Curr Pharm Des 24(41):4853\u20134859","journal-title":"Curr Pharm Des"},{"issue":"7","key":"2655_CR8","doi-asserted-by":"publisher","first-page":"1375","DOI":"10.1097\/IAE.0b013e31827d260a","volume":"33","author":"EYC Wang","year":"2013","unstructured":"Wang EYC (2013) Intravitreal anti-vascular endothelial growth factor for choroidal neovascularization secondary to pathologic myopia: systematic review and meta-analysis. Retina 33(7):1375\u20131392","journal-title":"Retina"},{"issue":"8","key":"2655_CR9","doi-asserted-by":"publisher","first-page":"e615","DOI":"10.1111\/aos.12457","volume":"92","author":"YH Kung","year":"2014","unstructured":"Kung YH, Wu, Huang YH (2014) One-year outcome of two different initial dosing regimens of intravitreal ranibizumab for myopic choroidal neovascularization. Acta Ophthalmol 92(8):e615\u2013e620","journal-title":"Acta Ophthalmol"},{"issue":"4","key":"2655_CR10","doi-asserted-by":"publisher","first-page":"196","DOI":"10.1159\/000478030","volume":"238","author":"C Calvo-Gonz\u00e1lez","year":"2017","unstructured":"Calvo-Gonz\u00e1lez C, Reche-Frutos J, Fern\u00e1ndez-Vigo JI, S\u00e1enz-Franc\u00e9s F, Fern\u00e1ndez-P\u00e9rezJ C, Garc\u00eda-Feij\u00f3o (2017) Long-term outcomes of two different initial dosing regimens of intravitreal Ranibizumab used to treat myopic choroidal neovascularization. Ophthalmologica 238(4):196\u2013204","journal-title":"Ophthalmologica"},{"issue":"6","key":"2655_CR11","doi-asserted-by":"publisher","first-page":"1220","DOI":"10.1016\/j.ophtha.2015.01.025","volume":"122","author":"Y Ikuno","year":"2015","unstructured":"Ikuno Y, Ohno-Matsui K, Wong TY et al (2015) Intravitreal aflibercept injection in patients with myopic choroidal neovascularization: the MYRROR study. Ophthalmology 122(6):1220\u20131227","journal-title":"Ophthalmology"},{"issue":"5","key":"2655_CR12","doi-asserted-by":"publisher","first-page":"e813","DOI":"10.1111\/aos.13632","volume":"97","author":"M Yan","year":"2019","unstructured":"Yan M, Huang Z, Lian HY, SongX YP, Chen (2019) Conbercept for treatment of choroidal neovascularization secondary to pathologic myopia. Acta Ophthalmol 97(5):e813\u2013e814","journal-title":"Acta Ophthalmol"},{"key":"2655_CR13","doi-asserted-by":"publisher","first-page":"156","DOI":"10.1016\/j.ajo.2018.08.026","volume":"197","author":"K Liu","year":"2019","unstructured":"Liu K, Song Y, Xu G et al (2019) Conbercept for treatment of neovascular age-related macular degeneration: results of the randomized Phase 3 PHOENIX Study. Am J Ophthalmol 197:156\u2013167","journal-title":"Am J Ophthalmol"},{"key":"2655_CR14","doi-asserted-by":"crossref","unstructured":"Liu K, Wang H, He W et al (2022) Intravitreal conbercept for diabetic macular oedema: 2-year results from a randomised controlled trial and open-label extension study. Br J Ophthalmol 106(10):1436\u20131443","DOI":"10.1136\/bjophthalmol-2020-318690"},{"issue":"1","key":"2655_CR15","doi-asserted-by":"publisher","first-page":"8010","DOI":"10.1038\/s41598-020-65000-5","volume":"10","author":"L Gao","year":"2020","unstructured":"Gao L, Liu J, Zhang P, MaH J, Wang (2020) Clinical outcomes of 1 + PRN and 3 + Q3M regimens of intravitreal conbercept injection for exudative age-related macular degeneration. Sci Rep 10(1):8010","journal-title":"Sci Rep"},{"issue":"10","key":"2655_CR16","doi-asserted-by":"publisher","first-page":"6886","DOI":"10.1167\/iovs.13-11665","volume":"54","author":"G Querques","year":"2013","unstructured":"Querques G, Srour M, Massamba N, Georges A, Ben Moussa N, Rafaeli O, Souied EH (2013) Functional characterization and multimodal imaging of treatment-naive \u201cquiescent\u201d choroidal neovascularization. Invest Ophthalmol Vis Sci 54(10):6886\u20136892","journal-title":"Invest Ophthalmol Vis Sci"},{"key":"2655_CR17","doi-asserted-by":"publisher","first-page":"92","DOI":"10.1016\/j.preteyeres.2017.10.005","volume":"63","author":"K Ohno-Matsui","year":"2018","unstructured":"Ohno-Matsui K, Ikuno Y, Lai TYY, Gemmy Cheung CM (2018) Diagnosis and treatment guideline for myopic choroidal neovascularization due to pathologic myopia. Prog Retin Eye Res 63:92\u2013106","journal-title":"Prog Retin Eye Res"},{"issue":"1","key":"2655_CR18","doi-asserted-by":"publisher","first-page":"9","DOI":"10.1016\/j.ajo.2013.08.010","volume":"157","author":"TY Wong","year":"2014","unstructured":"Wong TY, Ferreira A, Hughes R, CarterP G, Mitchell (2014) Epidemiology and disease burden of pathologic myopia and myopic choroidal neovascularization: an evidence-based systematic review. Am J Ophthalmol 157(1):9-25.e12","journal-title":"Am J Ophthalmol"},{"issue":"1","key":"2655_CR19","doi-asserted-by":"publisher","first-page":"116","DOI":"10.1186\/s12886-021-01877-8","volume":"21","author":"X Nie","year":"2021","unstructured":"Nie X, Wang Y, YiY H, Qiao (2021) Intravitreal conbercept for choroidal neovascularisation secondary to pathological myopia in a real-world setting in China\u202f: Intravitreal conbercept was safe and effective in treating myopic choroidal neovascularization. BMC Ophthalmol 21(1):116","journal-title":"BMC Ophthalmol"},{"issue":"11","key":"2655_CR20","doi-asserted-by":"publisher","first-page":"1415","DOI":"10.1080\/02713683.2020.1742357","volume":"45","author":"C Chen","year":"2020","unstructured":"Chen C, Yan M, Huang Z, Song YP (2020) The evaluation of a two-year outcome of intravitreal conbercept versus Ranibizumab for pathological myopic choroidal neovascularization. Curr Eye Res 45(11):1415\u20131421","journal-title":"Curr Eye Res"},{"issue":"9900","key":"2655_CR21","doi-asserted-by":"publisher","first-page":"1258","DOI":"10.1016\/S0140-6736(13)61501-9","volume":"382","author":"U Chakravarthy","year":"2013","unstructured":"Chakravarthy U, Harding SP, Rogers CA, Downes SM, Lotery AJ, Culliford LA, Reeves BC (2013) Alternative treatments to inhibit VEGF in age-related choroidal neovascularisation: 2-year findings of the IVAN randomised controlled trial. Lancet (London, England) 382(9900):1258\u20131267","journal-title":"Lancet (London, England)"},{"issue":"8","key":"2655_CR22","doi-asserted-by":"publisher","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","volume":"6","author":"HXJNC Chen","year":"2009","unstructured":"Chen HXJNC (2009) Adverse effects of anticancer agents that target the VEGF pathway. Nat Rev Clin Oncol 6(8):465\u2013477","journal-title":"Nat Rev Clin Oncol"},{"issue":"8","key":"2655_CR23","doi-asserted-by":"publisher","first-page":"1081","DOI":"10.1136\/bjo.2008.138891","volume":"92","author":"PA Keane","year":"2008","unstructured":"Keane PA, Liakopoulos S, Chang KT, Heussen FM, Ongchin SC, Walsh AC, Sadda SR (2008) Comparison of the optical coherence tomographic features of choroidal neovascular membranes in pathological myopia versus age-related macular degeneration, using quantitative subanalysis. Br J Ophthalmol 92(8):1081\u20131085","journal-title":"Br J Ophthalmol"},{"key":"2655_CR24","doi-asserted-by":"publisher","DOI":"10.3389\/fmed.2021.720804","volume":"8","author":"H Lu","year":"2021","unstructured":"Lu H, Yue T, Liu N et al (2021) Efficacy of Conbercept in the treatment of choroidal neovascularization secondary to pathologic myopia. Front Med (Lausanne) 8:720804","journal-title":"Front Med (Lausanne)"},{"issue":"7","key":"2655_CR25","doi-asserted-by":"publisher","first-page":"1007","DOI":"10.1016\/j.ophtha.2018.09.040","volume":"126","author":"MH Maloney","year":"2019","unstructured":"Maloney MH, Schilz SR, Herrin J, Sangaralingham LR, Shah ND, Barkmeier AJ (2019) Risk of systemic adverse events associated with intravitreal anti-VEGF therapy for diabetic macular edema in routine clinical practice. Ophthalmology 126(7):1007\u20131015","journal-title":"Ophthalmology"},{"issue":"12","key":"2655_CR26","doi-asserted-by":"publisher","first-page":"2347","DOI":"10.1097\/IAE.0000000000001489","volume":"37","author":"Y Ikuno","year":"2017","unstructured":"Ikuno Y (2017) Overview of the complications of high myopia. Retina 37(12):2347\u20132351","journal-title":"Retina"},{"issue":"3","key":"2655_CR27","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1016\/j.ophtha.2013.10.023","volume":"121","author":"S Wolf","year":"2014","unstructured":"Wolf S, Balciuniene VJ, Laganovska G et al (2014) RADIANCE: a randomized controlled study of ranibizumab in patients with choroidal neovascularization secondary to pathologic myopia. Ophthalmology 121(3):682\u201392.e2","journal-title":"Ophthalmology"},{"key":"2655_CR28","first-page":"2311","volume":"9","author":"XXS Lu","year":"2015","unstructured":"Lu XXS (2015) Profile of conbercept in the treatment of neovascular age-related macular degeneration. Drug Des Devel Ther 9:2311\u20132320","journal-title":"Drug Des Devel Ther"},{"issue":"12","key":"2655_CR29","doi-asserted-by":"publisher","first-page":"1467","DOI":"10.1080\/02713683.2020.1781193","volume":"45","author":"H Liu","year":"2020","unstructured":"Liu H, Ma Y, Xu HC, Huang LY, Zhai LY, Zhang XR (2020) Updates on the management of ocular vasculopathies with VEGF inhibitor Conbercept. Curr Eye Res 45(12):1467\u20131476","journal-title":"Curr Eye Res"}],"container-title":["International Ophthalmology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02655-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10792-023-02655-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10792-023-02655-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,9,15]],"date-time":"2023-09-15T10:17:29Z","timestamp":1694773049000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10792-023-02655-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,8,10]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2023,10]]}},"alternative-id":["2655"],"URL":"https:\/\/doi.org\/10.1007\/s10792-023-02655-9","relation":{},"ISSN":["1573-2630"],"issn-type":[{"value":"1573-2630","type":"electronic"}],"subject":[],"published":{"date-parts":[[2023,8,10]]},"assertion":[{"value":"3 August 2022","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"19 February 2023","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"10 August 2023","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors have no conflicts of interest to disclose relevant to this study.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"The study was approved by the ethics committee of The Second Affiliated Hospital of Guangzhou Medical University. Written informed consent was waived due to the retrospective nature of the study.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to Participate"}},{"value":"The Research Ethics Board approved our request to publish anonymized data for this study.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"No informed consent was obtained from participants as data collected were retrospective in nature and part of the standard of care examination. This was approved by the ethics committee of The Second Affiliated Hospital of Guangzhou Medical University and adhered to the Tenet\u2019s of Helsinki for retrospective studies.","order":5,"name":"Ethics","group":{"name":"EthicsHeading","label":"Informed consent"}}]}}